The Americas
EMEA
Asia Pacific
Global
Select a therapeutic area
21.9 %
Discover how IQVIA’s site targeting approach can boost the enrollment rate for your next study.
LET'S START A CONVERSATION TODAY
Up to
Enrollment Rate Comparison
95% CI: 15.7%, 28.7%; p<0.001
Non-Priority Sites
All Therapeutics
Enrollment rate increase with CORE-powered site targeting
UP TO
Click a therapeutic area and region to see more.
Explore the results!
Priority Sites
Respiratory
ONCOLOGY
Neurology
Infectious Diseases
Hematology
Cardiovascular
Endocrinology
Gastrointestinal
Rheumatology
95% CI: 23.2%, 50.7%; p<0.001
36.8 %
95% CI: 9.1%, 26.6%; p<0.001
17.5 %
18.3 %
95% CI: 10.2%, 26.4%; p<0.001
95% CI: -2.2%, 115.7%; p=0.037
54.0 %
24.6 %
Not Currently Statistically Significant
37.1 %
34.2 %
95% CI: 4.7%, 138.9%; p=0.014
3.4 %
30.5 %
95% CI: 5.5%, 81.4%; p=0.008
13.5 %
95% CI: -20.2%, 126.9%; p=0.050
47.2 %
34.8 %
12.2 %
95% CI: 25.0%, 91.6%; p<0.001
48.2 %
47.9 %
95% CI: 22.5%, 88.3%; p=0.001
51.8 %
95% CI: -6.3%, 91.7%; p=0.042
38.9 %
95% CI: -5.2%, 144.5%; p=0.039
41.9 %
39.9 %
39.0 %
15.7 %
95% CI: 15.9%, 67.9%; p<0.001
34.4 %
95% CI: 0.0%, 108.6%; p=0.011
41.3 %
32.8 %
95% CI: 5.6%, 22.0%; p<0.001
13.6 %
95% CI: -2.1%, 35.4%; p=0.038
17.3 %
95% CI: -0.3%, 22.4%; p=0.027
10.5 %
95% CI: 10.2%, 36.2%; p<0.001
22.3 %
95% CI: -1.0%, 41.4%; p=0.031
21.8 %
95% CI: 14.4%, 102.9%; p=0.008
12.4 %
95% CI: -1.8%, 54.5%; p=0.033
27.1 %
95% CI: 19.3%, 103.8%; p=0.002
60.6 %
60.6%
95% CI: 0.1%, 320.0%; p=0.025
87.1%
80.5 %
95% CI: -1.2%, 68.4%; p=0.029
87.1 %
